| pubmed-article:8382537 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8382537 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:8382537 | lifeskim:mentions | umls-concept:C0042774 | lld:lifeskim |
| pubmed-article:8382537 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:8382537 | lifeskim:mentions | umls-concept:C0162491 | lld:lifeskim |
| pubmed-article:8382537 | lifeskim:mentions | umls-concept:C0023983 | lld:lifeskim |
| pubmed-article:8382537 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8382537 | pubmed:dateCreated | 1993-4-1 | lld:pubmed |
| pubmed-article:8382537 | pubmed:abstractText | Hepatitis C virus RNA (HCV-RNA) and serological markers of HCV infection were measured in 30 patients with chronic hepatitis C who had been treated with interferon (IFN). Patients were classified into four groups according to serum alanine aminotransferase (ALT) levels after treatment. These were: as complete responders (CR); partial responders (PR); transient responders (TR); and non-responders (NR). In all 11 patients in the CR group, HCV-RNA disappeared from serum for at least 24 months and anti-c100-3 decreased progressively during this time. In the PR group, four of five patients were positive for HCV-RNA in spite of the improvement of ALT levels and decline of anti-c100-3. In the TR and NR groups, HCV-RNA disappeared transiently or remained persistently positive. The results indicate that IFN-mediated improvement of ALT and decrease of anti-HCV (anti-c100-3) were not always related to the disappearance of HCV-RNA from serum. On the other hand, sustained disappearance of HCV-RNA from serum was demonstrated in the patients who did not have post-treatment ALT relapse. This indicates that IFN can eradicate HCV from serum in some patients and provide a clinical remission of chronic hepatitis C. | lld:pubmed |
| pubmed-article:8382537 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8382537 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8382537 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8382537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8382537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8382537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8382537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8382537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8382537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8382537 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8382537 | pubmed:issn | 0815-9319 | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:KogaMM | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:InokuchiKK | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:NagatakiSS | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:UrdeaM SMS | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:KolbertGG | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:InoueOO | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:IrvineBB | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:DAYP EPE | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:YatsuhashiHH | lld:pubmed |
| pubmed-article:8382537 | pubmed:author | pubmed-author:StempienMM | lld:pubmed |
| pubmed-article:8382537 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8382537 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:8382537 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8382537 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8382537 | pubmed:pagination | 1-6 | lld:pubmed |
| pubmed-article:8382537 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:meshHeading | pubmed-meshheading:8382537-... | lld:pubmed |
| pubmed-article:8382537 | pubmed:articleTitle | Short and long-term effects of interferon on serum markers of hepatitis C virus replication. | lld:pubmed |
| pubmed-article:8382537 | pubmed:affiliation | Department of Clinical Research, Nagasaki Chuo National Hospital, Japan. | lld:pubmed |
| pubmed-article:8382537 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8382537 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8382537 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
